Explorium Logo

ERX Pharmaceuticals logo

erxpharmaceuticals.com

245 Main St Cambridge, Massachusetts 02142, US

ERX Pharmaceuticals

ERX Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the discovery and clinical development of innovative drugs to treat obesity and obesity-associated metabolic diseases. The company utilizes innovative science to restore human biology to its naturally designed state, with a focus on leptin biology and leptin resistance. ERX Pharmaceuticals was founded in 2014 based on discoveries by Dr. Umut Ozcan, aiming to develop leptin sensitizers as drug candidates for the treatment of obesity. Their flagship product, ERX-1000, has shown significant reductions in body weight in preclinical studies and is being developed for the treatment of obesity.

ERX Pharmaceuticals logo

ERX Pharmaceuticals

ERX Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the discovery and clinical development of innovative drugs to treat obesity and obesity-associated metabolic diseases. The company utilizes innovative science to restore human biology to its naturally designed state, with a focus on leptin biology and leptin resistance. ERX Pharmaceuticals was founded in 2014 based on discoveries by Dr. Umut Ozcan, aiming to develop leptin sensitizers as drug candidates for the treatment of obesity. Their flagship product, ERX-1000, has shown significant reductions in body weight in preclinical studies and is being developed for the treatment of obesity.

erxpharmaceuticals.com

245 Main St Cambridge, Massachusetts 02142, US

Details

Year founded

2014

Revenue

1M-5M

Employees

1-10

Number of locations

1

NAICS

3254

SIC

2834

Products & Services

Outlines the company's specialized services and operational strengths.

  • Leptin sensitizers
  • Contact us in order to access

Equipment

Provides a detailed list of machinery and tools utilized on the company's premises.

  • Leptin sensitizers for the treatment of obesity and related diseases
  • ERX-1000 drug candidate for obesity
  • ERX-2000 drug candidate for type 2 diabetes
  • Contact us in order to access

Ramping up production

Indicates the company's current production trend and growth trajectory.

TRUE

Our production algorithm is showing that erx pharmaceuticals is ramping up production.

Target industries

Medical
Pharmaceuticals
Biopharmaceuticals

Employees working in ERX Pharmaceuticals

Teo Uysal

Chief executive officer

Umut Ozcan

Scientific founder

Sandy Xu

Doctor of pharmacy

Sharon George

Supervising pharmacist

Employees working in ERX Pharmaceuticals

Teo Uysal

Chief executive officer

Umut Ozcan

Scientific founder

Sandy Xu

Doctor of pharmacy

Sharon George

Supervising pharmacist

Book a demo

Locations (1)

ERX Pharmaceuticals

245 Main St Cambridge, Massachusetts 02142, US

Frequently Asked Questions


ERX Pharmaceuticals offers a range of services and capabilities, including Leptin sensitizers.


Get the full services & capabilities list of ERX Pharmaceuticals

ERX Pharmaceuticals uses a variety of equipment, including Leptin sensitizers for the treatment of obesity and related diseases.


Get the full equipment list of ERX Pharmaceuticals

ERX Pharmaceuticals serves several industries, including the medical industry.


Get the full target industries list of ERX Pharmaceuticals

ERX Pharmaceuticals operates from a single location at 245 main street, cambridge, massachusetts 02142, united states.


Get a free locations and target markets review for ERX Pharmaceuticals

The headquarters of ERX Pharmaceuticals are located in 245 main street, cambridge, massachusetts 02142, united states.


Get a free locations and target markets review for ERX Pharmaceuticals

The NAICS code for ERX Pharmaceuticals is 3254.


Get a free business data review for ERX Pharmaceuticals

ERX Pharmaceuticals has 2 employees.


Get a free workforce data review of ERX Pharmaceuticals

The official website of ERX Pharmaceuticals is https://www.erxpharmaceuticals.com/.


ERX Pharmaceuticals was founded in 2014.